ProstAtak, Theragene, and the evolution of “vaccine-like” therapies for prostate cancer

In May this year we initially commented on a media announcement about a new form of vaccine-like therapy that was entering Phase III clinical trials for the first-line treatment of intermediate- and high-risk prostate cancer. … READ MORE …